<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02566564</url>
  </required_header>
  <id_info>
    <org_study_id>MTX-071-P01</org_study_id>
    <nct_id>NCT02566564</nct_id>
  </id_info>
  <brief_title>Intra-articular Lopain (MTX-071) Phase I/IIa Study in Chronic Osteoarthritic Knee Joint Pain</brief_title>
  <official_title>An Open Label, Single Dose, Dose-escalating Phase I/IIa Study to Determine the Safety and Clinical Effects of Intra-articular Injections of Lopain (MTX-071) in Patients With Chronic Osteoarthritic Knee Joint Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mestex AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mestex AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I/IIa study to determine the safety and clinical effects of intra-articular injections
      of MTX-071 (Lopain) in patients with chronic osteoarthritic knee-joint pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, single-dose, dose-escalating phase I/IIa study to determine the safety and
      clinical effects of intra-articular injections of MTX-071 (Lopain) in patients with chronic
      osteoarthritic knee-joint pain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intensity and severity of AES/SAEs potentially causally related with the study medication</measure>
    <time_frame>up to 6 months</time_frame>
    <description>overall and per dose level (descriptive statistics) incidence, intensity and severity of AES/SAEs potentially causally related with the study medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain relief response: overall and dose response</measure>
    <time_frame>up to 6 months</time_frame>
    <description>overall and per dose level percentage of patients overall percentage of patients with pain relief response to single intraarticular administration of Lopain (MTX-071) defined as more than a 20% decrease from baseline in mm on the VAS for pain on motion without increase in pain medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of pain relief response: overall and dose response</measure>
    <time_frame>up to 6 months</time_frame>
    <description>overall and per dose level intra-patients maintenance at 7 days, 1, 3 and 6 months of the pain relief response defined as more than a 20% decrease from baseline in mm on the VAS for pain on motion without increase in pain medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptance of / satisfaction with treatment as stated by the patients and physicians. (VAS score)</measure>
    <time_frame>up to 6 months</time_frame>
    <description>per dose level VAS score on acceptance of / satisfaction with treatment as stated by the patients and physicians.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of treatment on functionality of the knee joint and patients' general feeling of health and estimation of daily life conditions (VAS scores)</measure>
    <time_frame>up to 6 months</time_frame>
    <description>per dose level VAS scores on functionality of the knee joint and patients' general feeling of health and estimation of daily life conditions</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>open label, single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label, single arm, dose escalating</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopain</intervention_name>
    <description>intra-articular injection</description>
    <arm_group_label>open label, single arm</arm_group_label>
    <other_name>MTX-071</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Written informed consent

          -  Men or women aged between 40 and 70 years

          -  At least 40 mm on motion and at least 10 mm at rest on the 100 mm-VAS (Visual Analog
             Scale) for average arthritic joint pain in the knee to be studied during the last 2
             days, with or without pain medication.

          -  Previously documented radiography showing a Kellgren Lawrence Grade 2 - 4 severity.

          -  Female patients of childbearing potential or female partners of childbearing potential
             of male patients must agree to use a reliable contraceptive method for at least one
             month after the injection of MTX-071.

          -  Subject is highly likely to comply with the protocol and complete the study.

        Exclusion Criteria:

          -  Knee surgery within 6 months before study start or planned for any time during the
             next 6 months.

          -  Any injection into the knee to be studied within the preceding 7 days or trauma to the
             knee not yet healed.

          -  History of any clinically significant cardiac, renal, and/or other relevant disease or
             malignancy.

          -  History of severe allergic or anaphylactic reactions.

          -  Pregnancy.

          -  Major bleeding disorder.

          -  Clinically significant deviation from the normal laboratory values.

          -  Clinically significant abnormal ECG

          -  History of clinically relevant drug/chemical/ substance/alcohol abuse within the past
             2 years prior to screening.

          -  Symptomatic, viral, bacterial (including upper respiratory infection), or fungal
             (non-cutaneous) infection within the past 2 weeks prior to study medication
             administration.

          -  Patients positive for human immunodeficiency virus (HIV) antibody, hepatitis C
             antibody, or for hepatitis B virus surface antigen (HBsAg), tuberculosis.

          -  Patients who had a corticosteroid injection in the knee to be studied within 3 months
             prior to baseline or are planned to get a corticosteroid injection within 4 weeks
             following the injection of MTX-071.

          -  Vaccination within 60 days prior to study medication administration.

          -  Systemic immunosuppressant agent within 6 months prior to study medication
             administration

          -  Experimental agent within 30 days or ten half-lives, whichever is longer, prior to
             study medication administration.

          -  Any other condition, which in the opinion of the investigator, precludes the subject's
             participation in the trial.

          -  Patients who are dependent on the sponsor or investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Ramael</last_name>
    <role>Principal Investigator</role>
    <affiliation>SGS Antwerpen, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SGS Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2015</study_first_submitted>
  <study_first_submitted_qc>October 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2015</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Arthralgia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

